Structure-based drug discovery aims to identify small molecules that can attach to a specific target protein and change its functionality. Recently, deep learning has shown great promise in generating drug-like molecules with specific biochemical features and conditioned with structural features. However, they usually fail to incorporate an essential factor: the underlying physics which guides molecular formation and binding in real-world scenarios.
View Article and Find Full Text PDFThe use of fast in silico prediction methods for protein-ligand binding free energies holds significant promise for the initial phases of drug development. Numerous traditional physics-based models (e.g.
View Article and Find Full Text PDFAmberTools is a free and open-source collection of programs used to set up, run, and analyze molecular simulations. The newer features contained within AmberTools23 are briefly described in this Application note.
View Article and Find Full Text PDFCalculation of protein-ligand binding affinity is a cornerstone of drug discovery. Classic implicit solvent models, which have been widely used to accomplish this task, lack accuracy compared to experimental references. Emerging data-driven models, on the other hand, are often accurate yet not fully interpretable and also likely to be overfitted.
View Article and Find Full Text PDF